Compare SUVEN LIFE with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES PANACEA BIOTECH SUVEN LIFESCIENCES/
PANACEA BIOTECH
 
P/E (TTM) x 1.3 10.8 12.4% View Chart
P/BV x 0.4 2.3 15.7% View Chart
Dividend Yield % 6.4 0.0 -  

Financials

 SUVEN LIFESCIENCES   PANACEA BIOTECH
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
PANACEA BIOTECH
Mar-19
SUVEN LIFESCIENCES/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs338354 95.5%   
Low Rs169138 122.6%   
Sales per share (Unadj.) Rs52.174.6 69.9%  
Earnings per share (Unadj.) Rs6.86.7 102.3%  
Cash flow per share (Unadj.) Rs8.615.5 55.3%  
Dividends per share (Unadj.) Rs1.500-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs65.357.2 114.1%  
Shares outstanding (eoy) m127.2861.25 207.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.93.3 147.5%   
Avg P/E ratio x37.136.8 100.8%  
P/CF ratio (eoy) x29.615.9 186.4%  
Price / Book Value ratio x3.94.3 90.3%  
Dividend payout %22.00-   
Avg Mkt Cap Rs m32,27215,061 214.3%   
No. of employees `0001.12.3 46.8%   
Total wages/salary Rs m6611,471 45.0%   
Avg. sales/employee Rs Th6,132.21,973.6 310.7%   
Avg. wages/employee Rs Th611.1635.6 96.1%   
Avg. net profit/employee Rs Th803.5176.8 454.5%   
INCOME DATA
Net Sales Rs m6,6354,567 145.3%  
Other income Rs m24245 540.8%   
Total revenues Rs m6,8774,612 149.1%   
Gross profit Rs m1,6042,030 79.0%  
Depreciation Rs m221540 41.0%   
Interest Rs m381,048 3.6%   
Profit before tax Rs m1,587486 326.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m71877 931.2%   
Profit after tax Rs m869409 212.5%  
Gross profit margin %24.244.4 54.4%  
Effective tax rate %45.215.9 285.2%   
Net profit margin %13.19.0 146.3%  
BALANCE SHEET DATA
Current assets Rs m6,2322,415 258.1%   
Current liabilities Rs m1,4909,077 16.4%   
Net working cap to sales %71.5-145.9 -49.0%  
Current ratio x4.20.3 1,572.4%  
Inventory Days Days8665 132.8%  
Debtors Days Days8371 116.5%  
Net fixed assets Rs m4,0438,333 48.5%   
Share capital Rs m12761 207.7%   
"Free" reserves Rs m8,1833,443 237.7%   
Net worth Rs m8,3103,504 237.2%   
Long term debt Rs m18461 3.9%   
Total assets Rs m10,38913,755 75.5%  
Interest coverage x43.11.5 2,944.8%   
Debt to equity ratio x00.1 1.6%  
Sales to assets ratio x0.60.3 192.4%   
Return on assets %8.710.6 82.4%  
Return on equity %10.511.7 89.6%  
Return on capital %19.538.7 50.4%  
Exports to sales %020.9 0.0%   
Imports to sales %08.1 0.0%   
Exports (fob) Rs mNA954 0.0%   
Imports (cif) Rs mNA372 0.0%   
Fx inflow Rs m5,6221,203 467.3%   
Fx outflow Rs m1,799467 385.6%   
Net fx Rs m3,822736 519.1%   
CASH FLOW
From Operations Rs m3561,049 33.9%  
From Investments Rs m-279-54 520.7%  
From Financial Activity Rs m-225-1,011 22.3%  
Net Cashflow Rs m-148-20 752.3%  

Share Holding

Indian Promoters % 63.4 74.5 85.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.6 -  
FIIs % 0.0 1.3 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 23.6 154.7%  
Shareholders   37,287 10,259 363.5%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   ALEMBIC PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare SUVEN LIFESCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 271 Points Higher; Capital Goods and Realty Stocks Rally(Closing)

Indian share markets witnessed buying interest during closing hours today and ended higher. Benchmark indices regained momentum amid huge buying seen in capital goods and realty stocks.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Jan 10, 2020

The story behind my latest stock recommendation and an important announcement.

Bet on These Smallcap Stocks for Success in 2020(Profit Hunter)

Jan 14, 2020

The smallcap rebound finally seems to here... Make sure you aren't too late to make the most of the biggest wealth making opportunity in a decade.

Guess Which Stocks Are Rising at Double the Speed of Sensex(Profit Hunter)

Jan 15, 2020

These stocks can move twice as fast as the Sensex - to take advantage of their money multiplying power get in now as the rally is still just taking shape.. read more to not miss out.

For 1,000%+ Gains, Follow the 8-Year Cycle in the Stock Market(Fast Profits Daily)

Jan 17, 2020

This is how the biggest trading profits are made.

What the Infosys Results Tell Us About the Next Infosys(The 5 Minute Wrapup)

Jan 15, 2020

If you're interested in the next Infosys, I'll tell you where to look.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Jan 23, 2020 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES - ALEMBIC PHARMA COMPARISON

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS